NiKang Therapeutics

An early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs

News and Events

WILMINGTON, Del., Nov. 04, 2019 (GLOBE NEWSWIRE) -- NiKang Therapeutics, an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced the appointment of Y. Peter Li, Ph.D., MBA, as Chief Executive Officer and Board Director. Dr. Li has over 18 years of in-depth experience as a successful executive at innovative biotech companies with his most recent role as co-founder and founding CEO and Chairman for Turning Point Therapeutics, Inc.

“Peter’s broad knowledge and demonstrated success in biotech entrepreneurship, corporate financing and development, business development, and executive management are invaluable as we continue to build on the strong foundation of NiKang,” said Sean Cao, Board Director of NiKang. “We welcome Peter to the NiKang team, and look forward to leveraging his extensive experience and insights during this exciting and important period of growth for the company.”
“I am very delighted to join NiKang Therapeutics’ dedicated team of talented and experienced biopharmaceutical professionals. This is an exciting time at NiKang as we advance our unique oncology pipeline towards clinical trials. I look forward to working with the team and applying our collective expertise to advance and eventually deliver transformative medicines to cancer patients,” said Dr. Li.

Dr. Li is the co-founder and founding CEO of Turning Point Therapeutics, Inc. (TP), a clinical-stage biotech company. Dr. Li served as Chairman and CEO of TP from 2013 to 2018 and continued to serve as a Director until TP completed a successful $191 million IPO on Nasdaq in April 2019. As Chairman and CEO, Dr. Li led TP for 5 years and successfully raised 4 rounds of venture financing for $147 million in total from leading biotech investors. TP has built a strong pipeline with the lead compound Repotrectinib entering pivotal Phase 2 clinical trial and two additional projects expected to enter clinical development in 2019. Prior to TP, Dr. Li served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics. Prior to Epitomics, Dr. Li was Vice President at Kenson Ventures, LLC, where he served on Board of Directors and observers to the Board for biotech companies. He earned his M.B.A. from Haas School of Business, University of California, Berkeley. He received his Ph.D. in biochemistry from Ohio State University, where he was a University Presidential Fellow, and his B.S. from the University of Science and Technology of China.

>>Original Article